ong-term efficacy and safety of Limaprost for the treatment of Lumbar Spinal Stenosis
Not Applicable
Not yet recruiting
- Conditions
- umbar Spinal Stenosis
- Registration Number
- JPRN-UMIN000012918
- Lead Sponsor
- Kansai LSS Forum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1) SLR positive 2) Current or history of critical limb ischemia 3) Uncontrolled DM 4) Diagnosis of RA 5) Clinically significant neurological or skeletal dysfunction 6)Unlikely to be compliant with protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Zurich claudication questionnaire
- Secondary Outcome Measures
Name Time Method Intermittent claudication MOS-Short Form 12 Numeric Rating Scale(NRS) for pain and numbness intensity Measurement of treatment satisfaction Combined medicine and treatment Surgery rate EQ-5D
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Limaprost in treating Lumbar Spinal Stenosis (LSS)?
How does Limaprost compare to epidural steroid injections in long-term LSS management?
Are there specific biomarkers that predict Limaprost response in patients with degenerative LSS?
What are the potential adverse events associated with prolonged Limaprost administration for LSS?
What other prostaglandin analogs or combination therapies show promise in LSS treatment research?